Back to the main directory
EarningsReview / Equity
- HK to cap commissions on regular premium participating products: implications for Pru by BNP Paribas Exane
- Warn, spin, or both? by BNP Paribas Exane
- Filtronic - Upgrading on stronger H225 expectations by Edison Investment Research
- Phonebook 3Q24 by BNP Paribas Exane
- Feedback post company contact by BNP Paribas Exane
- Growing rapidly, but slower than anticipated by BNP Paribas Exane
- Feedback post company contact by BNP Paribas Exane
- Recce Pharmaceuticals - BPOM clearance to start Phase III R327G study by Edison Investment Research
- Feedback post company contact by BNP Paribas Exane
- 1Q25e (due: 12 Feb. 2025) - pre-close call feedback by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Activist presentation: our key takeaways by BNP Paribas Exane
- Feedback from pre-close call by BNP Paribas Exane
- This is how you outperform, 2025 edition by BNP Paribas Exane
- Nissan-Honda to explore potential merger? by BNP Paribas Exane
- Elektroimportøren (Buy, TP: NOK14.50) - Set for brighter 2025 by DnB Markets
- Nokia (Buy, TP: EUR5.20) - 2025e sisu starting to build by DnB Markets
- First award confirmed under Petrobras ‘rig pool’ tender by DnB Markets
- Prices, volumes, arbitrage opportunities, and implications on company profits by BNP Paribas Exane
- Special Enough? by BNP Paribas Exane
- Catching up with management: Q4 preclose call feedback by BNP Paribas Exane
- RIIO-T3 business plan publication by BNP Paribas Exane
- INVEST SECURITIES - SCBSM : Un profil amélioré avec discpline - ACHAT (vs NEUTRE), OC 10,9€ (vs 9,2€) by Invest Securities
- Q4 24 pre close by BNP Paribas Exane
- Pan African Resources - Honing FY25e forecasts by Edison Investment Research
- Q4 pre-close: deflation weighing for longer than expected by BNP Paribas Exane
- Mid-quarter guide - Another big EPS miss… but expected as well by BNP Paribas Exane
- STLD, NUE, X, BHP, RIO. STEEL US by BNP Paribas Exane
- Basilea Pharmaceutica - Partner in place for US commercialisation of Zevtera by Edison Investment Research
- Feedback from pre-close call by BNP Paribas Exane
- Newron Pharmaceuticals - Evenamide licence agreement in Japan by Edison Investment Research
- Feedback post company contact by BNP Paribas Exane
- Feedback post company contact by BNP Paribas Exane
- German Federal Court of Justice may overturn Cost of Equity court case by BNP Paribas Exane
- Phoenix Spree Deutschland - Enhanced realisation strategy to unlock value by Edison Investment Research
- Wise announces partnership with Morgan Stanley for cross-border corporate payments by BNP Paribas Exane
- Key clean energy points from the CDU manifesto by BNP Paribas Exane
- Early thoughts ahead of Q4 results by BNP Paribas Exane
- What could a Nissan / Honda merger mean for Dassault Systèmes? by BNP Paribas Exane
- Essity (Buy, TP: SEK350.00) - Focus likely to be on 2025 by DnB Markets
- Ericsson (Buy, TP: SEK100.00) - Set to cut a dash by DnB Markets
- Valuation update by DnB Markets
- Twice Baked Potatoes by BNP Paribas Exane
- Feedback from US marketing by BNP Paribas Exane
- Returning to growth is the best you can do by BNP Paribas Exane
- Sale of US onshore projects by BNP Paribas Exane
- STEEL EU, MT, COAL by BNP Paribas Exane
- INVEST SECURITIES - TOOSLA : Feuille de route respectée à fin 2024 - ACHAT, OC 2,6€ by Invest Securities
- Preclose call: 4Q to reflect improving GLP-1 dynamics; CagriSema data still due shortly by BNP Paribas Exane
- 4Q24 Pre-call takeaways by BNP Paribas Exane